Long-term efficacy of intravenously administered immunoglobulin in a case of polymyositis with limited application of steroid therapy

Nakamura, Hideki; Fujikawa, Keita; Kawakami, Atsushi; Tamai, Mami; Yamasaki, Satoshi; Ida, Hiroaki; Eguchi, Katsumi

doi:10.1007/s10165-010-0298-2

Cited by 3 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most clinical studies, their levels were measured to evaluate disease activity and to identify relapse of myositis or refractory diseases. In all of the 26 studies published in the major journals between 1993 and 2012, serum CK and aldolase levels were measured and considered as indicators of myositis relapse …”

Section: Methodsmentioning

confidence: 99%

“…In most clinical studies, MMT was assessed to evaluate disease activity and to identify relapse of myositis or refractory diseases. In 23 of the 26 studies published in the major journals between 1993 and 2012, MMT scores were considered as an indicator of myositis relapse . Although the MMT scores are good markers in considering intensification of treatment, clinicians should rule out muscle weakness attributable to steroid‐induced myopathy.…”

Section: Methodsmentioning

confidence: 99%

“…In all of the 26 studies published in the major journals between 1993 and 2012, serum CK and aldolase levels were measured and considered as indicators of myositis relapse. 4,39,47,69,71,83,[89][90][91][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][110] MMT (recommendation grade: B): Although no validated definitions of relapse are available, deterioration of MMT scores has been used as an indicator of relapse. In most clinical studies, MMT was assessed to evaluate disease activity and to identify relapse of myositis or refractory diseases.…”

Section: Cq4 What Is the First-line Treatment For Pm And Dm?mentioning

confidence: 99%

See 2 more Smart Citations

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Kohsaka

Mimori

Kanda³

et al. 2018

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

Although rheumatologists, neurologists, and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of this study was to establish the treatment consensus among specialists of the three fields to standardize the patient care. We formed a research team supported by a grant from the Ministry of Health, Labor, and Welfare, Japan. Clinical questions (CQ) on the management of PM and DM were raised. A published work search on CQ was performed primarily using PubMed. Using the nominal group technique, qualified studies and results in the published work were evaluated and discussed to reach consensus recommendations. They were sent out to the Japan College of Rheumatology, Japanese Society of Neurology, and Japanese Dermatological Association for their approval. We reached a consensus in 23 CQ and made recommendations, and a decision tree for management was proposed. They were officially approved by the three scientific societies. In conclusion, a multidisciplinary treatment consensus for the management of PM and DM was established for the first time.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Cq4 What Is the First-line Treatment For Pm And Dm?mentioning

confidence: 99%

See 1 more Smart Citation

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Kohsaka

Mimori

Kanda³

et al. 2018

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

show abstract

“…In most clinical studies, MMT was assessed to evaluate disease activity and to identify relapse of myositis or refractory diseases. In 23 out of the 26 studies published in the major journals between 1993 and 2012, MMT scores were considered as an indicator of myositis relapse . Although the MMT scores are good markers in considering intensification of treatment, clinicians should rule out muscle weakness attributable to steroid‐induced myopathy.…”

Section: Treatment Consensusmentioning

confidence: 99%

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Kohsaka

Mimori

Kanda

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Although rheumatologists, neurologists and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of the present study was to establish the treatment consensus among specialists of the three fields to standardize the patient care. We formed a research team supported by a grant from the Ministry of Health, Labor and Welfare, Japan. Clinical questions (CQ) on the management of PM and DM were raised. A published work search on CQ was performed primarily using PubMed. Using the nominal group technique, qualified studies and results in the published work were evaluated and discussed to reach consensus recommendations. They were sent out to the Japan College of Rheumatology, Japanese Society of Neurology and Japanese Dermatological Association for their approval. We reached a consensus in 23 CQ and made recommendations and a decision tree for management was proposed. They were officially approved by the three scientific societies. In conclusion, a multidisciplinary treatment consensus for the management of PM and DM was established for the first time.

show abstract

“…IVIG therapy added to GC appears to be effective, as demonstrated in a double-blind, placebo-controlled trial of patients with refractory DM (2 g/kg in divided doses over 3 days) 79 and an open study of patients with PM 80 . The longterm efficacy of IVIG with or without GC use has been suggested in 3 case reports of patients with PM 81,82,83 . Biological immunotherapy.…”

Section: Glucocorticoids (Gc)mentioning

confidence: 99%

Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies

Lazarou

Guerne²

2013

J Rheumatol

View full text Add to dashboard Cite

The detection and characterization of a large array of autoantibodies, including at least 8 different antisynthetase, anti-SRP, -200/100 (HMGCR), -Mi-2, -CADM-140 (MDA5), -SAE, -p155, -MJ (NXP-2), and -PMS1, frequently associated with distinct and well-defined clinicopathological features, allowed for significant improvement in the definition and diagnosis of idiopathic inflammatory myopathies (IIM). Classification remains difficult, with lingering divergence between the different specialties involved in IIM care, but several categories clearly stand out, including dermatomyositis (DM), overlap myositis (OM), polymyositis, necrotizing myositis, and sporadic inclusion body myositis (s-IBM). Biopsy and histological analysis remain crucial, particularly in the absence of autoantibodies, to accurately specify the diagnosis and rule out mimics such as muscular dystrophies and metabolic myopathies. Numerous infectious agents (in particular human immunodeficiency virus and human T cell lymphotrophic virus-1) and drugs (statins, tumor necrosis factor inhibitors, and proton pump inhibitors) can cause mimic IIM that must also be excluded. Pharmacological treatment, in addition to glucocorticoids and immunoglobulins, now includes mycophenolate mofetil and rituximab, which proved helpful in resistant cases, particularly rituximab in DM and OM. Exercise, initially seen as potentially deleterious, recently was shown to be efficacious and safe. IIM can thus be reasonably well controlled in most cases, although aggressive disease remains refractory to treatment, including some cases of necrotizing myopathy. Sporadic IBM still seems resistant to all medications tested to date.

show abstract

Long-term efficacy of intravenously administered immunoglobulin in a case of polymyositis with limited application of steroid therapy

Cited by 3 publications

References 9 publications

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies

Contact Info

Product

Resources

About